Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation
Cardiology · 2024
DOI: 10.1159/000538551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology, 2024. Verfasst von Fuyuan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Lishui People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Mendelian Randomization Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertase 9. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with significant clinical implications. The potential influence of lipid-lowering therapies, specifically PCSK9 inhibitors (PCSK9i) and HMG-CoA reductase inhibitors (statins), on AF risk remains a topic of interest. This mendelian randomization (MR) study aimed to elucidate the causal relationship between genetically predicted inhibition of PCSK9 and HMG-CoA reductase and the risk of AF.
Methods
Utilizing publicly available, summary-level genome-wide association study data, we employed single-nucleotide polymorphisms associated with lower LDL-C levels as instruments for gene-simulated inhibition of PCSK9 and HMG-CoA reductase. Multiple MR techniques were applied to estimate the causal effects, and sensitivity analyses were conducted to validate the results.
Results
Genetically predicted inhibition of PCSK9 demonstrated a reduced risk of AF, with an odds ratio (OR) of 0.92 (95% CI: 0.85–0.99, p = 0.01) using the inverse variance-weighted (IVW) method. In contrast, the inhibition of HMG-CoA reductase did not exhibit a statistically significant association with AF risk (IVW: OR = 1.11, 95% CI: 1.00–1.22, p = 0.05).
Conclusion
Our MR study suggests that genetically predicted inhibition of PCSK9, but not HMG-CoA reductase, is associated with a lower risk of AF. These findings provide evidence for a causal protective effect of PCSK9i on AF and support the use of PCSK9i for AF prevention in patients with dyslipidemia. Further studies are needed to elucidate the mechanisms underlying the differential effects of PCSK9i and statins on AF and to confirm the clinical implications of our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Lishui People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
- Department of Cardiology, First Affiliated Hospital of Lishui University School of Medicine, Lishui, China.
Zitieren
APA
Li, F., Mei, Y., Wu, Q., & Wu, X. (2024). Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation. Cardiology. https://doi.org/10.1159/000538551
Vancouver
Li F, Mei Y, Wu Q, Wu X. Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation. Cardiology. 2024. doi:10.1159/000538551
BibTeX
@article{Li2024,
author = {Li, Fuyuan and Mei, Yibin and Wu, Qiongbi and Wu, Xianjun},
title = {Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation},
journal = {Cardiology},
year = {2024},
doi = {10.1159/000538551}
}
EUVIMED